We Help Companies Find New Sales Opportunities
SmithKline Beecham is to acquire Block Drug, the US toothpaste company, for £850m, in order to expand its dental care division.
SmithKline Beecham has sold three pharmaceutical products in order to help secure approval for its merger with Glaxo Wellcome, with Famvir and Vectavir going to Novartis and Kytril to Roche.
SmithKline Beecham is investing £6m in a new bottling centre for Lucozade and Ribena at its Forest of Dean factory.
SmithKline Beecham has awarded a £5m contract to Walter Lilly for the refurbishment of laboratories in Harlow, Essex.
SmithKline Beecham is selling Diversified Pharmaceutical Services, the pharmacy benefit business, to Express Scripts of the US for £427m, and its US clinical labs to Quest Diagnostics for £625m.
SmithKline Beecham has confirmed that it is in merger discussions with American Home Products to create the world's largest pharmaceuticals group with sales of about £16bn.
SmithKline Beecham has acquired Abtei Pharma Vertreibs, the German consumer medicines concern, for £91m.
SmithKline Beecham is moving into healthcare management in South Africa, with the acquisition of Total Support Management.